FEDERAL COURT OF AUSTRALIA
Arrow Pharmaceuticals Limited v Merck & Co Inc [2004] FCA 129
PRACTICE AND PROCEDURE – application revocation of Australian patent – whether particulars of invalidity adequate – lack of novelty and inventive steps alleged – subsequent amendment of particulars – discussion of privilege of medical practitioner – whether case as pleaded and particularised should proceed to trial.
Patents Act 1990 (Cth) s 7(1), (2), 18(1)
Evidence Act 1995 (Cth)Terrell on the Law of Patents (15th ed) par 7.04
Federal Court Rules Order 58 rule 15Stanway Oyster Cylinders Pty Ltd v Marks (1996) 35 IPR 71
Merrell Dow Pharmaceuticals Inc and Others v H.N. Norton & Co Ltd (1995) IPR 1
General Steel Industries Inc v Commissioner for Railways (NSW) (1964) 112 CLR 125
Dey v Victorian Railways Commissioners (1949) 78 CLR 62
Fomento Industrial SA., Biro Swan Ltd and Another v Mentmore Manufacturing Coy Ltd (1956) RPC 87
ICI Chemicals and Polymers Ltd v Lubrizol Corporation (1999) 45 IPR 577
Chiron Corporation v Organon Teknika Limited (No 3) [1994] FSR 202
RD Werner & Co Inc v Bailey Aluminium Products Pty Ltd (1989) 13 IPR 513
Conde Nast Publications Pty Ltd v Taylor (1998) 41 IPR 505
National Research Development Corporation v Commissioner of Patents (1959) 102 CLR 252
Minnesota Mining and Manufacturing Company v Beiersdorf (Australia) Limited (1980) 144 CLR 253
Sunbeam Corporation v Morphy-Richards (Aust) Pty Ltd (1961) 180 CLR 98
Merell Dow Pharmaceutical Inc v H.N. Norton & Co Ltd (1996) PRC 76
Windsurfing International Inc v Petit (1983-1985) 2 IPR 449 at 484-490ARROW PHARMACEUTICALS LIMITED v MERCK AND CO INC
N 1211 OF 2002
CONTI J
23 FEBRUARY 2004
SYDNEY
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
N 1211 OF 2002
BETWEEN:
ARROW PHARMACEUTICALS LIMITED
APPLICANTAND:
MERCK & CO INC.
RESPONDENTJUDGE:
CONTI J
DATE OF ORDER:
23 FEBRUARY 2004
WHERE MADE:
SYDNEY
THE COURT ORDERS THAT:
1.The respondent’s notice of motion filed on 10 November 2003 be dismissed otherwise than to the extent that the parties have mutually agreed.
2.The costs of the respondent’s applications the subject of the notice of motion be stood over for further submissions in the light of the reasons for judgment.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
N 1211 OF 2002
BETWEEN:
ARROW PHARMACEUTICALS LIMITED
APPLICANTAND:
MERCK & CO INC.
RESPONDENT
JUDGE:
CONTI J
DATE:
23 FEBRUARY 2004
PLACE:
SYDNEY
REASONS FOR JUDGMENT
Background
Subsequently to delivery of reasons for interlocutory judgment on 27 June 2003, the respondent Merck & Co Inc. (‘Merck’) sought the following relief against the applicant Arrow Pharmaceuticals Ltd (‘Arrow’) by notice of motion filed on 10 November 2003:
(i)A declaration that the Further Amended Particulars of Invalidity filed by Arrow on 25 July 2003 and the further particulars set out in a letter dated 10 September 2003 from Arrow’s…
Keep reading for free
Create a free CaseChat account to read Arrow Pharmaceuticals Limited v Merck and Co Inc and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2004] FCA 129
- Decision Date
CaseChat Overview and Summary
The primary legal issues that the court needed to address were the sufficiency of the particulars provided by Arrow in relation to the prior art information, and whether the acts identified by Arrow constituted a public disclosure of this information. The court further examined the application of Order 58 rule 15 of the Federal Court Rules, which governs the particularity required in affidavit evidence. The court had to decide whether the acts of the medical practitioners constituted the "occasion" for the application of this rule, and whether further discovery was necessary. Additionally, the court considered the potential applicability of patient privilege in the context of medical practitioners' treatment of unidentified sick or injured persons.
The court found that the December 2003 Particulars provided by Arrow appeared to comply adequately with Order 58 rule 15(2) concerning the professional conduct and practices of the medical practitioners. The court emphasised that the rule does not require an excessive level of specificity regarding the times, places, and other related circumstances of the issuance of prescriptions. The court held that the existence of any patient privilege would not apply to the treatment of unidentified sick or injured persons, as this would not intrude into the private affairs of any identifiable individual. The court dismissed the respondent's notice of motion, except to the extent that the parties had mutually agreed. The costs of the respondent's applications were stood over for further submissions in light of the reasons for judgment.
ORDERS:
1. The respondent’s notice of motion filed on 10 November 2003 is dismissed otherwise than to the extent that the parties have mutually agreed.
2. The costs of the respondent’s applications, which are the subject of the notice of motion, are stood over for further submissions in light of the reasons for judgment.
Orders
Orders of the court
1. The respondent’s notice of motion filed on 10 November 2003 be dismissed otherwise than to the extent that the parties have mutually agreed.
2. The costs of the respondent’s applications the subject of the notice of motion be stood over for further submissions in the light of the reasons for judgment.
Background
Background to the litigation
The matter came before the court through a notice of motion filed by Merck on 10 November 2003. This motion sought orders in relation to the adequacy of particulars provided by Arrow. The court heard arguments from both parties and reviewed the material evidence and submissions. The court examined the submissions from both sides, including the affidavit evidence from Arrow concerning the professional conduct and practices of the medical practitioners and the identification of relevant medical journals. The court also considered Merck's challenges to the adequacy of Arrow's particulars. The court examined the evolution of the parties' contentions and the procedural issues that arose, including the application of Order 58 rule 15.
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Established by: CONTI J
The court thoroughly examined the submissions of both parties regarding the adequacy of particulars and the issue of public availability of prior art information. It found that Arrow's December 2003 Particulars met the requirements of Order 58 rule 15(2) in relation to the professional conduct of the medical practitioners and the identification of relevant medical journals. The court noted that while there may be room for further discovery, the current particulars were sufficient for the purposes of the application of the rule. Regarding the public availability of prior art information, the court concluded that this was a matter to be determined at trial based on all the evidence legitimately and realistically available. The court also considered the potential implications of patient privilege but found that it would not apply in the context of unidentified sick or injured persons. This decision highlights the court's approach to ensuring procedural fairness while allowing the case to progress to trial for a comprehensive examination of the facts.